Feiba is approved by the Food and Drug Administration (FDA) to control and prevent bleeding in people with hemophilia A and B who have developed inhibitors. Feiba can also be used for perioperative (before, during, and after surgery) care and for routine prophylaxis. The technical name of Feiba is Anti-inhibitor coagulant complex.
Feiba is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.
How do I take it?
Prescribing information states that Feiba is given as an intravenous injection.
Feiba comes as a powder that must be reconstituted before injection.
The FDA-approved label for Feiba lists common side effects including anemia, nausea, vomiting, diarrhea, and bleeding into joints.
Rare but serious side effects listed for Feiba include the transmission of infections, thromboembolic events, and life-threatening hypersensitivity reactions.
For more details about this treatment, visit:
Treatment of Hemophilia – Hemophilia Federation of America